This agent silences MGMT expression and enhances TMZ efficacy in GBM, consequently inducing cell cycle arrest by upregulating CDKN1A and impairing DNA repair via the ATF3-p38-E2F1 pathway, suggesting the potential of the combination treatment with TMZ [76]. The gene discussed is MAPK1; the disease is glioblastoma.